Saxenda 'in 5 steps': what the TikTok leaves out

What did @endocrino.cruces actually say?

Honestly? It's hard to tell. The transcript for this 577K-view TikTok is nearly incomprehensible, likely the result of auto-captioning a Spanish-language video. The creator appears to be walking through a step-by-step guide for using Saxenda (liraglutide) correctly, which the caption confirms: "Usa SAXENDA correctamente en solo 5 pasos." But the actual content, the specific instructions, the dosing guidance, the administration tips, none of that survived the transcription process intact.

What we can infer from the caption, the hashtags, and the creator's handle (@endocrino.cruces, suggesting an endocrinology focus) is that this video was attempting to explain proper Saxenda injection technique and titration protocol. That's a clinically relevant topic. Whether they got it right is harder to assess without a clean transcript. We're rating what we can verify, and flagging the gaps.

Does the science back up how Saxenda should be used?

The general framework for correct Saxenda use is well-established. The question is whether this video taught it accurately. The evidence on liraglutide administration is not ambiguous, and the manufacturer protocol is specific enough that errors are easy to spot if you know what to look for.

Saxenda (liraglutide 3 mg) is a GLP-1 receptor agonist approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. The FDA-approved titration schedule starts at 0.6 mg once daily for one week, increasing by 0.6 mg weekly until reaching the 3 mg maintenance dose. This slow titration exists for a reason: the most common adverse effects, nausea, vomiting, diarrhea, are dose-dependent, and rushing the schedule significantly increases dropout rates. Pi-Sunyer et al. (2015, NEJM) demonstrated in the SCALE Obesity trial that patients who completed the full titration and reached 3 mg lost significantly more weight than those who could not tolerate the dose escalation.

Injection technique also matters. Saxenda is injected subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites reduces the risk of lipohypertrophy. The pen should not be shared, needles should be changed with each injection, and the medication should be stored refrigerated until first use, then can be kept at room temperature for up to 30 days.

What did they get wrong, or right?

We cannot fairly accuse @endocrino.cruces of specific errors because the transcript is not usable. That is not a pass. It is a limitation of this review. What we can say is that the category of content, a step-by-step Saxenda tutorial, carries real risk if done poorly.

Common mistakes in GLP-1 social media content include: skipping the titration schedule to get faster results, treating the 3 mg dose as optional rather than the therapeutic target, ignoring contraindications like personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and failing to mention that Saxenda is not the same drug as semaglutide or tirzepatide despite being in the same drug class. These are not minor omissions. A 2023 analysis by Moniuszko-Malinowska and colleagues in Frontiers in Endocrinology noted that patient-facing GLP-1 content on social media frequently omits contraindication information, which can lead to unsupervised use in people for whom the drug is not safe.

The creator's apparent clinical background is a point in their favor. An endocrinologist explaining injection technique is more credible than a wellness influencer doing the same. But credibility is not a substitute for a verifiable transcript.

What should you actually know about using Saxenda correctly?

If you are on Saxenda or considering it, the "5 steps" framing is reasonable but the details matter more than the structure. Here is what the clinical evidence actually supports.

• Do not skip the titration. The slow dose escalation is not a suggestion. Patients who rush to 3 mg without titrating report significantly higher rates of nausea and are more likely to discontinue the medication entirely.
• Saxenda requires a prescription and ongoing medical supervision. It is not a short-term fix. The SCALE Maintenance trial (Wadden et al., 2013, Obesity) showed that stopping liraglutide leads to weight regain, which means this is a long-term commitment, not a course of treatment with a defined end date.
• Saxenda and Ozempic (semaglutide) are not the same drug. They work on the same receptor but have different molecular structures, dosing schedules, and clinical trial profiles. Do not substitute one for the other based on social media advice.
• Common side effects are real and manageable. Nausea affects roughly 40% of patients in clinical trials. Eating smaller meals, avoiding high-fat foods, and taking the injection at a consistent time each day can reduce GI discomfort.
• If you experience severe abdominal pain, discontinue use and seek medical attention. Pancreatitis is a rare but serious risk associated with GLP-1 receptor agonists.

The bottom line on this video

A 577K-view tutorial on Saxenda from a creator with an apparent endocrinology background could be genuinely useful, or it could be missing critical safety information. We cannot tell from this transcript. What we can say is that anyone using Saxenda based on social media guidance alone is taking on unnecessary risk. This drug class has real contraindications, a specific titration protocol, and requires monitoring that a TikTok cannot provide. Watch the video if you want, but verify everything with the clinician who prescribed it.